Drugs / BNT162b2 Monovalent (OMI XBB.1.5)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05541861 | Nov 2022 → Nov 2024 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162b2 Monovalent (OMI XBB.1.5) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541861 ↗ |
| Route | Intramuscular | “administered as intramuscular injection.” NCT05541861 ↗ |